Comparison of Isotope Ratio Mass Spectrometry and Nondispersive Isotope-Selective Infrared Spectroscopy for 13C-Urea Breath Test

Savarino, Vincenzo; Mela, Giuseppe Sandro; Zentilin, Patrizia; Bisso, G.; Pivari, Monica; Mansi, C.; Mele, Maria Raffaella; Bilardi, C.; Vigneri, Sergio; Celle, G

doi:10.1111/j.1572-0241.1999.01067.x

Cited by 74 publications

(54 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…General features of the patients were consistent with our previous study (20) and with larger studies carried out at our unit (27). All patients included in the study completed the 1-week eradication therapy.…”

Section: Resultsmentioning

confidence: 86%

Influence of 1-Week Helicobacter pylori Eradication Therapy with Rabeprazole, Clarithromycin, and Metronidazole on 13C-Aminopyrine Breath Test

et al. 2005

Self Cite

View full text Add to dashboard Cite

Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C-aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (to), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 +/- 5.4, t8 = 13.5 +/- 4.0, t38 = 16.1 +/- 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 +/- 1.1, t8 = 2.4 +/- 0.8, t38 = 2.6 +/- 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.

show abstract

Section: Resultsmentioning

confidence: 86%

Influence of 1-Week Helicobacter pylori Eradication Therapy with Rabeprazole, Clarithromycin, and Metronidazole on 13C-Aminopyrine Breath Test

et al. 2005

Self Cite

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10][11] In our study, the mean Ϯ 2SD of the difference in ∆ 13 C values between the two methods was 0.34 Ϯ 1.06‰, and the 95% confidence interval for the difference in ∆ 13 C values between the two methods included zero. In the range where the mean of the ∆ 13 C values determined by the two methods was 30‰ or higher, although there were some cases in which the difference in ∆ 13 C values exceeded the mean Ϯ 2SD, there were no cases in which the difference between the ∆ 13 C values determined by the two methods exceeded 5‰, which was considered to have been due to the very small SD of Ϯ0.53‰.…”

Section: Discussionmentioning

confidence: 99%

“…In comparison with an IRMS, this low-cost device is attractive not only from a technological point of view but also with regard to precision, 6,7 and there have been a growing number of reports of the 13 C-UBT being performed using an NDIRS. [8][9][10] In the present study, we analyzed 13 CO 2 in expired breath, using a UBiT-IR300 (Otsuka Electronics, Osaka, Japan), which is the latest model in the previously reported UBiT Series of infrared spectrophotometers, 11,12 and which requires no nitrogen gas to perform measurements. We quantitatively and qualitatively compared the ∆ 13 C values measured using the UBiT-IR300 with those measured using an IRMS (ABCA-G; Europa Scientific, Crewe, UK), and, employing assessment by a combination of biopsy methods as a reference standard, we evaluated the diagnostic performance of the 13 C-UBT, using the UBiT-IR300 in the assessment of H. pylori infection.…”

Section: Methodsmentioning

confidence: 99%

13C-Urea breath test, using a new compact nondispersive isotope-selective infrared spectrophotometer: comparison with mass spectrometry

et al. 2004

View full text Add to dashboard Cite

show abstract

“…After overnight fasting, duplicate breath samples were collected at baseline and 30 min after urea ingestion. A mass spectrometry device was used to measure the 13 C/ 12 C ratio 16 . A delta value> 5‰ was considered positive.…”

Section: Methodsmentioning

confidence: 99%

Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection

Savarino

Zentilin

Bisso

et al. 1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

INTRODUCTIONAt present, 1-week proton pump inhibitor-based triple therapy is the most recommended regimen for the treatment of H. pylori infection.1 From the ®rst successful experience of Bazzoli and his group, 2 other clinical trials, both small and large 3,4 have con®rmed the ef®cacy of this short-term multiple treatment. In recent years, however, the novel compound ranitidine bismuth citrate (RBC) has been shown to be an effective antiHelicobacter drug when combined with clarithromycin for 14 days.5 In relation to the good results of 1-week proton pump inhibitor-based triple therapy, we have recently shown that shortening the treatment with RBC plus low-dose clarithromycin and metronidazole to SUMMARY Background: Ranitidine bismuth citrate (RBC) co-prescribed with clarithromycin and metronidazole for 1 week has been shown to be an effective eradicating regimen for Helicobacter pylori. Aim: To determine the optimal duration of this regimen. Methods: A series of 165 dyspeptic patients were recruited for this randomized, open, parallel-group study. They were subdivided into three groups receiving RBC 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for three different periods (4, 7 and 10 days). H. pylori infection was assessed by the concomitant positivity of CLO-test and histology performed at the pre-entry endoscopy. The bacterium was considered eradicated on the basis of a negative 13 Curea breath test performed at least 28 days after the completion of treatment. Results: The three subgroups were well matched and 16 patients dropped out of the study for many reasons (six

show abstract

Comparison of Isotope Ratio Mass Spectrometry and Nondispersive Isotope-Selective Infrared Spectroscopy for 13C-Urea Breath Test

Abstract: Infrared spectroscopy can be considered a valid alternative to mass spectroscopy for the diagnosis of H. pylori infection. Fasting is required to guarantee an accurate test.

Cited by 74 publications

References 9 publications

Influence of 1-Week Helicobacter pylori Eradication Therapy with Rabeprazole, Clarithromycin, and Metronidazole on 13C-Aminopyrine Breath Test

Influence of 1-Week Helicobacter pylori Eradication Therapy with Rabeprazole, Clarithromycin, and Metronidazole on 13C-Aminopyrine Breath Test

13C-Urea breath test, using a new compact nondispersive isotope-selective infrared spectrophotometer: comparison with mass spectrometry

Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection

Contact Info

Product

Resources

About